Item 8.01. Other Events.

On January 21, 2021, United Therapeutics Corporation (the "Company") closed the transaction to acquire a Rare Pediatric Disease Priority Review Voucher ("PRV"), previously announced on December 28, 2020. At closing, the Company paid $105.0 million in exchange for the PRV. The Company has submitted notice to the U.S. Food and Drug Administration of its intent to redeem the voucher upon submission of its upcoming New Drug Application ("NDA") for Tyvaso DPI™.

TYVASO DPI is a trademark of United Therapeutics Corporation.

© Edgar Online, source Glimpses